Imugene valuation points to 129% upside as broker backs azer-cel strategy

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) could be significantly undervalued as its focused push into allogeneic CAR-T therapy gathers momentum, according...